THERAPY DOSSIER · th-7ec9fce9719e

C3a receptor agonist

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23696668 ↗2013Reported benefit

The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization.

MouseIschaemia-reperfusionIntestinal / mesentericC3aR-deficient and wild-type mice

Model: Neutrophil-dependent intestinal ischaemia-reperfusion injury

A potent C3a agonist reduced neutrophil mobilisation and ameliorated intestinal ischaemia-reperfusion pathology in wild-type but not C3aR-deficient mice.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…